These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 6726217)

  • 1. Suppression of REM rebound by Pergolide.
    Askenasy JJ; Yahr MD
    J Neural Transm; 1984; 59(2):151-9. PubMed ID: 6726217
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Reversal of sleep disturbance in Parkinson's disease by antiparkinsonian therapy: a preliminary study.
    Askenasy JJ; Yahr MD
    Neurology; 1985 Apr; 35(4):527-32. PubMed ID: 3982638
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Clinical study of pergolide in Parkinson's disease].
    Gonce M; Delwaide PJ
    Presse Med; 1985 Jun; 14(26):1409-11. PubMed ID: 3161045
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pergolide and lisuride in advanced Parkinson's disease.
    Lieberman AN; Gopinathan G; Neophytides A; Leibowitz M; Goldstein M
    Adv Neurol; 1984; 40():503-7. PubMed ID: 6695627
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Long-term efficacy of pergolide in patients with Parkinson's disease.
    Sage JI; Duvoisin RC
    Clin Neuropharmacol; 1986; 9(2):160-4. PubMed ID: 3708601
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pergolide in the treatment of Parkinson's disease.
    Quinn NP; Lang AE; Thompson C; Brincat S; Marsden CD; Parkes JD
    Adv Neurol; 1984; 40():509-13. PubMed ID: 6695628
    [No Abstract]   [Full Text] [Related]  

  • 7. Chronic agonist therapy for Parkinson's disease: a 5-year study of bromocriptine and pergolide.
    Goetz CG; Tanner CM; Glantz RH; Klawans HL
    Neurology; 1985 May; 35(5):749-51. PubMed ID: 3990974
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Long-term experience with pergolide therapy of advanced parkinsonism.
    Kurlan R; Miller C; Levy R; Macik B; Hamill R; Shoulson I
    Neurology; 1985 May; 35(5):738-42. PubMed ID: 3887213
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The use of pergolide, a potent dopamine agonist, in Parkinson's disease.
    Lieberman AN; Goldstein M; Neophytides A; Leibowitz M; Gopinathan G; Walker R; Pact V
    Clin Pharmacol Ther; 1982 Jul; 32(1):70-5. PubMed ID: 7083733
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Controlled trial of pergolide mesylate in Parkinson's disease and progressive supranuclear palsy.
    Jankovic J
    Neurology; 1983 Apr; 33(4):505-7. PubMed ID: 6339985
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Parkinson's disease: new drugs help but no cure on the horizon.
    González ER
    JAMA; 1981 Jul; 246(1):11-2. PubMed ID: 7241717
    [No Abstract]   [Full Text] [Related]  

  • 12. Mesulergine and pergolide in previously untreated Parkinson's disease.
    Wright A; Lees AJ; Stern GM
    J Neurol Neurosurg Psychiatry; 1987 Apr; 50(4):482-4. PubMed ID: 3585362
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy of pergolide and mesulergine.
    Lieberman AN; Gopinathan G; Neophytides A
    Eur Neurol; 1986; 25(2):86-90. PubMed ID: 3948891
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pergolide mesylate: new therapy for Parkinson disease.
    Tanner CM; Klawans HL
    Ann Intern Med; 1982 Apr; 96(4):522-3. PubMed ID: 7065569
    [No Abstract]   [Full Text] [Related]  

  • 15. Painful dystonic spasms in Parkinson's disease.
    Ilson J; Fahn S; Côté L
    Adv Neurol; 1984; 40():395-8. PubMed ID: 6695618
    [No Abstract]   [Full Text] [Related]  

  • 16. [Multiple latency test in a patient with episodes of sleep induced by pergolide].
    Jiménez-Jiménez FJ; Velasco I; de Toledo M; Sayed Y; Zurdo J; Ortí-Pareja M
    Rev Neurol; 2002 Jun 16-30; 34(12):1140-1. PubMed ID: 12134281
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effect of pergolide mesylate, an ergoline, in animal models of Parkinson's disease: implications for therapy.
    Koller WC; Diamond BI; Weiner WJ; Nausieda PA; Klawans HL
    Trans Am Neurol Assoc; 1979; 104():161-4. PubMed ID: 553398
    [No Abstract]   [Full Text] [Related]  

  • 18. Burden of cardiovascular diseases in elderly with Parkinson's disease who start a dopamine agonist agent.
    Trifirò G; Morgante L; Tari M; Arcoraci V; Savica R
    J Am Geriatr Soc; 2008 Feb; 56(2):371-3. PubMed ID: 18251828
    [No Abstract]   [Full Text] [Related]  

  • 19. Polysomnographic characterization of pergolide-induced sleep attacks in idiopathic PD.
    Ulivelli M; Rossi S; Lombardi C; Bartalini S; Rocchi R; Giannini F; Passero S; Battistini N; Lugaresi E
    Neurology; 2002 Feb; 58(3):462-5. PubMed ID: 11839851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The use of pergolide and lisuride, two experimental dopamine agonists, in patients with advanced Parkinson disease.
    Lieberman AN; Leibowitz M; Gopinathan G; Walker R; Hiesiger E; Nelson J; Goldstein M
    Am J Med Sci; 1985 Sep; 290(3):102-6. PubMed ID: 4050844
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.